Press Release 16th April 2018

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of empagliflozin in people with chronic kidney disease.

https://www.boehringer-ingelheim.com/EMPA-KIDNEY